

## Buwchitin

Oyama, Linda B.; Crochet, Jean-Andrien; Edwards, Joan E.; Girdwood, Susan E.; Cookson, Alan R.; Fernandez-Fuentes, Narcis; Hilpert, Kai; Golyshin, Peter; Golyshina, Olga; Prive, Florence; Hess, Matthiass; Mantovani, Hilario C.; Creevey, Christopher J.; Huws, Sharon A.

## Frontiers in Chemistry

Published: 12/07/2017

Peer reviewed version

[Cyswllt i'r cyhoeddiad / Link to publication](#)

*Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):*

Oyama, L. B., Crochet, J-A., Edwards, J. E., Girdwood, S. E., Cookson, A. R., Fernandez-Fuentes, N., Hilpert, K., Golyshin, P., Golyshina, O., Prive, F., Hess, M., Mantovani, H. C., Creevey, C. J., & Huws, S. A. (2017). Buwchitin: A Ruminal Peptide with Antimicrobial Potential against *Enterococcus faecalis*. *Frontiers in Chemistry*.

### Hawliau Cyffredinol / General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

# **Buwchitin: a ruminal peptide with antimicrobial potential against *Enterococcus faecalis***

Linda B Oyama<sup>1</sup>, Jean-Adrien Crochet<sup>1,2</sup>, Joan E Edwards<sup>1,3</sup>, Susan E Girdwood<sup>1</sup>, Alan R Cookson<sup>1</sup>, Narcis Fernandez-Fuentes<sup>1</sup>, Kai Hilpert<sup>4</sup>, Peter N Golyshin<sup>5</sup>, Olga V Golyshin<sup>5</sup>, Florence Privé<sup>1</sup>, Matthias Hess<sup>6</sup>, Hilario C Mantovani<sup>7</sup>, Christopher J Creevey<sup>1</sup>, Sharon A Huws<sup>8\*</sup>.

<sup>1</sup> Aberystwyth University, Aberystwyth, Wales, United Kingdom.

<sup>2</sup> (Current address) Université de Bretagne Occidentale, Brest, France.

<sup>3</sup> (Current address) Wageningen University & Research, Wageningen, Netherlands.

<sup>4</sup> Institute of Infection and Immunity, St George's University of London, United Kingdom.

<sup>5</sup> Bangor University, Bangor, Gwynedd, United Kingdom.

<sup>6</sup> UC Davis, College of Agricultural and Environmental Sciences, California, United States of America.

<sup>7</sup> Department of Microbiology, Universidade Federal de Viçosa, Viçosa, Brazil.

<sup>8</sup> School of Biological Sciences, Medical Biology Centre, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.

**Running title:** Novel antimicrobial compounds from the cow microbiome.

## **\*Correspondence:**

Dr. Sharon A. Huws, Reader in Animal Science, School of Biological Sciences, Medical Biology Centre, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland, UK. E-mail: Sharon.huws@qub.ac.uk. Phone no: (044) 0289097 6514.

**Number of words: 9101**

**Number of Figures and Tables combined: 7**

## **Abstract**

Antimicrobial peptides (AMPs) are gaining popularity as alternatives for treatment of bacterial infections and recent advances in *omics* technologies provide new platforms for AMP discovery. We sought to determine the antibacterial activity of a novel antimicrobial peptide, buwchitin, against *Enterococcus faecalis*. Buwchitin was identified from a rumen bacterial metagenome library, cloned, expressed and purified. The antimicrobial activity of the recombinant peptide was assessed using a broth microdilution susceptibility assay to determine the peptide's killing kinetics against selected bacterial strains. The killing mechanism of buwchitin was investigated further by monitoring its ability to cause membrane depolarization (diSC<sub>3</sub>(5) method) and morphological changes in *E. faecalis* cells. Transmission electron micrographs of buwchitin treated *E. faecalis* cells showed intact outer membranes with blebbing, but no major damaging effects and cell morphology changes. Buwchitin had negligible cytotoxicity against defibrinated sheep erythrocytes. Although no significant membrane leakage and depolarization was observed, buwchitin at minimum inhibitory concentration (MIC) was bacteriostatic against *E. faecalis* cells and inhibited growth *in vitro* by 70% when compared to untreated cells. These findings suggest that buwchitin, a rumen derived peptide, has potential for antimicrobial activity against *E. faecalis*.

**Keywords:** microbiome, metagenomics, rumen bacteria, antibiotic resistance, antimicrobial peptides, antimicrobial activity, *Enterococcus faecalis*.

## Introduction

*Enterococcus faecalis* is a non-motile, Gram-positive, facultative anaerobic lactic acid bacterium of about 0.6-2.0  $\mu\text{m}$  in size, that grows as individual cells, in pairs or as short multicellular filaments (Leavis et al. 2006, Ch. Schroder et al. 2015). It tolerates a wide variety of growth conditions, including temperatures between 10-45°C, hypotonic, hypertonic, acidic, or alkaline environments (Ch. Schroder et al. 2015). *E. faecalis* is normally a gut commensal found in many animals and in the environment (Gilmore et al. 2013). It is also a frequent cause of many serious human infections, including urinary tract infections, endocarditis, bacteremia, and wound infections alongside *Enterococcus faecium* (Kau et al. 2005, Gilmore et al. 2013, Cahill and Prendergast). *E. faecalis* causes a variety of healthcare associated infections of which urinary tract infections are the most common (Kau et al. 2005, Hidron et al. 2008, Arias and Murray 2012, Gilmore et al. 2013). Infections with *E. faecalis* can be especially challenging to treat because of their frequent resistance to multiple antibiotics, including aminoglycosides, and vancomycin, which is considered as drug of last resort for many Gram-positive infections (Baddour et al. 2005, Hollenbeck and Rice 2012, Young et al. 2016). Vancomycin-resistant enterococci (VRE) are significant opportunistic pathogens in the hospital environment and often possess a multidrug-resistant phenotype (Chavers et al. 2003, van Harten et al. 2017) and their potential to spread enterococcal vancomycin resistance to other species remains a concern (Chang et al. 2003). VRE are also listed as priority pathogens by the World Health Organization for research and development of new antibiotics (WHO 2017). It is therefore important to develop new drugs for the treatment of enterococcal infections.

Continued development of new drugs by the pharmaceutical industry, aided by genomics, high-throughput screening, rational drug design, and novel therapies offer a very promising prospect of effective bactericidal monotherapy for Enterococci and long-term solutions to VRE (Eliopoulos and Gold 2001). Antimicrobial peptides (AMPs) are an integral part of the innate host defense system of many organisms including vertebrates, invertebrates, plants and bacteria (Wiesner and Vilcinskas 2010), with broad spectrum activity against several groups of organisms including multidrug resistant bacteria, fungi, viruses and parasites (Jenssen et al. 2006). Due to this, AMPs represent one of the most promising alternatives to antibiotics, and future strategies for defeating the threat of antimicrobial resistance in bacterial infections might depend on peptide-based antimicrobial molecules (Czaplewski et al. 2016, O'Neill 2016).

The rumen is one of the most diverse ecosystems in nature, harboring a microbial community, composed of a complex mixture of bacteria, protozoa, fungi, and viruses (Church 1993, Sirohi et al. 2012) commonly referred to as the rumen microbiome, and enzymes isolated from this ecosystem have the potential to possess very unique biochemical properties (Hess et al. 2011, Ross et al. 2012). Several ruminal bacteriocins have been identified to date, but all of these bacteriocins are derived from bacteria that can be grown in the laboratory (Russell and Mantovani 2002, Azevedo et al. 2015). Culture independent methods can be used to assess the rumen microbiome and increase the repertoire of bacteriocins, and other novel antimicrobials. It is possible to access and explore the total genetic information of this underexplored, uncultured fraction of the microbiome associated with any defined ecosystem through the application of metagenomics (Handelsman et al. 1998, Ekkers et al. 2012), which is the analysis of the DNA from a microbiome. Direct cloning of genomic or metagenomic DNA also offers the opportunity to capture genes encoding the synthesis of novel antimicrobials (Schloss and Handelsman 2003), whether from species with already known antimicrobial properties (bacteriocin production), or from completely new species.

Previously, we prospected a 8,448 clone fosmid-based rumen bacterial metagenomic library generated from cow rumen solid attached bacteria (SAB) for novel antimicrobials, combining both functional and sequence based metagenomics and *in silico* mining (Oyama 2015, Prive et al. 2015). From this work, we identified numerous AMPs and mini proteins. Results of the activity screens of the identified short AMPs ( $\leq 25$  AA) were reported elsewhere (Oyama 2015). One of the longer proteins, buwchitin (71 AA) was selected for further characterization due to its potential activity against *E. faecalis*. In this study, we report the potential antimicrobial activity of buwchitin against *E. faecalis*.

## Materials and methods

### **Bacterial strains and vectors**

Bacterial strains used for antimicrobial activity testing were provided in-kind by Bath University. Strains include methicillin sensitive *Staphylococcus aureus* (MSSA) RN4220, *Escherichia coli* K12, *Salmonella enterica* serovar Typhimurium SL1344, *Listeria monocytogenes* NCTC 11994 (serovar 4b) and *Enterococcus faecalis* JH2-2. *E. coli* TOP10 (Invitrogen, Carlsbad CA, USA) was used for cloning (to host expression vectors for protein expression). The pTrcHis TOPO® vector (Invitrogen, Carlsbad, CA, USA) was used to clone polymerase chain reaction (PCR) products for protein expression.

### **Bacteriological media and culture conditions**

Mueller Hinton (MH) (Sigma-Aldrich UK) and Luria Bertani (LB) broth and agar (Fisher Scientific Leicestershire, UK) were used as growth media. When leakage assays were performed under buffered conditions, 5 mM HEPES (pH 7.2) supplemented with 5 mM glucose was used (Wu and Hancock 1999). Media were prepared and sterilized according to the manufacturers' instructions. Bacterial strains were grown using standard conditions unless otherwise specified. Broth cultures were incubated at 37°C for 18-20 h with aeration and cultures on solid media were incubated at 37°C for 18-24 h.

### **Identification of antimicrobial genes from fosmid metagenomic library by agar based functional screening and sequencing analysis**

Antimicrobial genes were identified from the fosmid metagenomic library as previously described (Oyama 2015). Briefly, sterile pin replicators (Molecular Devices Ltd, Berkshire UK) were used to transfer 2  $\mu$ l metagenomic clones onto LB agar plates that had been plated before with 500  $\mu$ l ( $OD_{600nm} = 1$ ) of pathogens such as *S. aureus*, *E. coli*, *Sal. Typhimurium*, *E. faecalis* and *L. monocytogenes*. Plates were incubated at appropriate temperatures for 24 h and zones of clearing around the clones were used to identify clones with inserts encoding antimicrobials. Putative antimicrobial positive fosmid clones were sequenced using Roche's 454 pyrosequencing platform. BLASTN (v2.2.28) on NCBI and BioEdit (version 7.1.11) (Hall 1999) were used to edit and trim the vector sequence from the contigs. VecScreen on NCBI was used to search the sequences for vector contamination. Open reading frames (ORFs) were determined using the NCBI ORF finder program (Wheeler et al. 2003) and all ORFs with homology to antimicrobial genes and/or peptides were collated (Table 1). Based on expression levels and final protein yield, an ORF composed of 71 amino acids and named buwchitin was further investigated. Here, we report the activity of buwchitin.

#### ***Amplification of antimicrobial genes***

Extracted fosmid DNA (1 µl) from a metagenomic clone containing the buwchitin insert was used as template for PCR amplification. The buwchitin sequence was deposited in the GenBank database with accession number KY823515 and predicted to contain a signal peptide, when analyzed on the SignalP 4.1 server (Petersen et al. 2011). Primers were designed to start and stop at the first predicted methionine and at the last stop codon respectively in order to conserve the reading frame and take account of the entire gene of interest. The primers used for the amplification of buwchitin gene were 5'-ATGAGGCTGTCACACGTTTG-3' (forward primer) and 5'-TCACCAATCTGTATGGCACCG-3' (reverse primer). Primers were diluted to a stock concentration of 100 µM and a total volume of 50 µl PCR reaction was set up as follows: 2 µl DNA template, 1 µl each of the forward and reverse primers (2 µM final concentration), 39.5 µl molecular grade water and 1 µl Titanium<sup>®</sup> *Taq* DNA Polymerase (Clontech- Takara Bio Europe/SAS, France). *Taq* polymerase was activated for 1 minute at 95°C, followed by 30 cycles of 95°C for 30 seconds, 68°C for 1.5 minutes, followed by a final extension step at 68°C for 1.5 minutes. PCR products were verified by electrophoresis on a 1.5% agarose gel using a 1 kb DNA ladder. Gel image was taken after exposure to UV using the Gel Doc<sup>™</sup> XR<sup>+</sup> system (BIO-RAD Hertfordshire, UK). Subsequently, the band of interest was excised with a sterile scalpel under a Dark Reader blue transilluminator (Clare Chemical Research Inc. USA) and DNA was purified and eluted using the QIAquick Gel Extraction Kit (Qiagen, Crawley, UK) according to manufacturer guidelines.

#### ***Cloning of buwchitin gene and confirmation of cloning reaction***

Cloning of buwchitin was carried out using the pTrcHis TOPO<sup>®</sup> TA Expression kit as described by the manufacturer. Five positive colonies from the transformation were analyzed for correct size, sequence and orientation of the insert. Selected colonies were cultured overnight in LB medium containing 100 µg/ml ampicillin and 0.5% glucose, and analyzed by PCR. Briefly, aliquots (1 ml) were lysed by heating for 10 mins at 95°C in sterile 1.5 ml microcentrifuge tubes. The cell debris was pelleted by centrifugation at 13,000 × g for 2 mins. The supernatant was used as template for the subsequent PCR. The PCR was set up in a total volume of 50 µl as follows: 2 µl of template DNA, 1 µl of each gene specific forward primer (5'-ATGAGGCTGTCACACGTTTG-3') and vector specific reverse primer (5'-GATTTAATCTGTATCAGG-3'), 21 µl molecular grade water and 25 µl MyTaq<sup>™</sup> Red Mix (Bioline, UK Ltd, London UK). Initial *Taq* activation was performed at 95°C for 1 min, followed by 35 cycles of 95°C for 15 sec, at insert specific annealing temperature for 15 sec with an extension step at 72°C for 10 sec, and a final extension step at 72°C for 7 mins and holding at 4°C. PCR products were verified by electrophoresis on a 1.5% agarose gel using a 500bp DNA ladder. A positive PCR control was also prepared using the control PCR template (expected size of 750 bp) and primers provided with the pTrcHis-TOPO<sup>®</sup> expression kit. Positive transformants were further analyzed by Sanger sequencing using plasmid DNA from extracted positive transformants as templates. The Xpress<sup>™</sup> Forward sequencing primer for pTrcHis-TOPO<sup>®</sup> (5'-TATGGCTAGCATGACTGGT-3') was then used to sequence the insert and alignments to original sequence orientation was confirmed using BioEdit (Hall 1999).

#### ***Expression and purification of His-tagged buwchitin***

A single recombinant *E. coli* colony from a clone confirmed as containing the buwchitin gene was inoculated into LB broth containing 100 µg/ml ampicillin and grown overnight at 37°C with aeration and agitation (225-250 rpm). The following day, 1 L of LB broth containing 100 µg/ml ampicillin was inoculated with 20 ml of the overnight culture and incubated at 37°C under aeration (225-250 rpm). Gene expression was induced at OD<sub>600nm</sub> = 0.6 with 1 mM IPTG. Cells were harvested after 4 h by centrifugation (3,000 × g for 10 mins at 4°C) and cell pellets

were stored at -80°C for subsequent protein purification. Simultaneous purification and concentration of the buwchitin protein was carried out under native conditions using the Amicon® Pro Purification System (Merck Millipore Ltd Carrigtwohill, Ireland) following the manufacturer's protocol. Protein concentration was calculated as the ratio of absorbance at 280 nm (BioTek's Epoch™ Multi-Volume Spectrophotometer, (BioTek Instruments, Inc. Vermont, USA)) to the extinction coefficient absorbance (Abs 0.1% = 1 g/l calculated using the ExPASy ProtParam tool) (Gasteiger et al. 2005).

#### **Determination of minimum inhibitory concentration (MIC) of buwchitin**

Vancomycin, Polymyxin B sulfate and ciprofloxacin were purchased from Sigma-Aldrich (Poole, Dorset, United Kingdom). All stock solutions were dissolved in the appropriate solvent prior to dilution in sterile distilled water (Andrews, 2001). MICs of buwchitin was measured by broth microdilution method using two-fold serial dilutions of antimicrobial agents in MH broth (CLSI. 2012). Buwchitin or comparator agents, vancomycin hydrochloride, polymyxin B sulfate and ciprofloxacin were added to the wells of a 96-well plate containing bacteria from overnight culture (adjusted to  $1 \times 10^8$  CFU/ml) to achieve a final inoculum concentration of  $5 \times 10^5$  CFU/ml (Cherkasov et al. 2008, Wiegand et al. 2008). MIC was defined as the lowest concentration of test agent that inhibited visible growth of the organism after 18-24 h of incubation at 37°C.

#### **Bactericidal/bacteriostatic activity of buwchitin**

The bactericidal or bacteriostatic activity of buwchitin against *E. faecalis* was measured at MIC concentration using optical density measurements. An increase in both cell mass and cell number can readily be estimated by measuring the turbidity of a cell suspension using a spectrophotometer, thereby offering a rapid and sensitive alternative to cell counting (Dalgaard and Koutsoumanis 2001, Madrid and Felice 2005). This method has been shown to produce comparable results to plate counting, flow cytometric and green fluorescence viability analyses methods (Lehtinen et al. 2006). In a 96 well plate, buwchitin was added to cells in mid-logarithmic phase ( $1 \times 10^6$  CFU/ml, OD<sub>600nm</sub> of  $\leq 0.2$ ) in MH broth and serially diluted as previously described. Plates were incubated at 37°C in a microplate incubator shaker. Wells without antimicrobial agents were used as growth control while wells with MH broth alone served as negative control. The rate of kill was calculated as a percentage (OD<sub>600nm</sub>) of surviving cells over a 24 h period (Lehtinen et al. 2006, Hazan et al. 2012). The percentage of viable cells was normalized to 100% for the growth control (cells without antibiotic treatment).

#### **Erythrocyte leakage assay**

The ability of buwchitin to lyse red blood cells was assessed in a 96 well plate using defibrinated sheep blood (Oxoid Ltd Hampshire, UK). Sheep red blood cells (RBC) washed and diluted (4%) in phosphate buffered saline (35 mM PBS) (pH 7.3) were treated with buwchitin at different concentrations and incubated at 37°C for 1 h. Triton X-100 (0.1% causes 100% cell lysis) served as a positive control. Absorbance (OD<sub>450nm</sub>) of the supernatant (70 µl) from each well of the plate was measured to detect hemoglobin leakage from the erythrocyte cytoplasm and obtained results were used to determine the percentage hemolysis given that the 0.1% Triton X-100 represented 100% lysis after normalizing auto-hemolysis (PBS only treatment).

#### **Inner membrane depolarization assay (diSC3(5) method)**

The ability of buwchitin to disrupt the electrochemical potential across the bacterial cytoplasmic membrane was measured by determining the amount of the membrane-associated probe, 3,3'-dipropylthiadicarbocyanine iodide [diSC<sub>3</sub>(5)] released from the cytoplasm. (Wu et

al. 1999, Lee et al. 2004). Briefly, mid-logarithmic phase ( $OD_{600nm} = 0.2$ ) *E. faecalis* cells were washed and resuspended to an  $OD_{600nm}$  of 0.05 in 5 mM HEPES-glucose buffer, pH 7.2. In a 96-well plate, the cell suspension was incubated with 100 mM potassium chloride (KCl) and 0.4 mM 3,3'-dipropylthiadicarbocyanine iodide [diSC<sub>3</sub>(5)] until a stable reduction of fluorescence (excitation  $\lambda$  622 nm, emission  $\lambda$  670 nm) was achieved (approximately 1 h). The KCl was added to equilibrate the cytoplasmic and external K<sup>+</sup>. After 1 h, buwchitin, positive control agent (0.1% Triton X-100) or negative control agent (untreated cells) were added to the cells in the wells. The plate was further incubated at 37°C with shaking while fluorescence was continuously monitored (excitation  $\lambda$  622 nm, emission  $\lambda$  670 nm) upon addition of peptide at 2 to 5 minute intervals for 2 h.

### **Transmission electron microscopy (TEM)**

Exponential phase cultures of *E. faecalis* grown in MH broth were washed and resuspended to an  $OD_{600nm}$  of 0.2 in 10 mM PBS. The cell suspensions (1 ml) were incubated at 37°C with buwchitin at 1x MIC concentration in microcentrifuge tubes. To investigate possible changes in cell morphology following exposure to buwchitin, samples were removed at 1 h and 24 h after exposure and prepared for TEM as previously described (Huws et al. 2013). Briefly, samples were fixed with 2.5% (v/v) glutaraldehyde, after which they were post-fixed with 1% (w/v) osmium tetroxide. Fixed samples were then stained with 2% (w/v) uranyl acetate and Reynold's lead citrate and observed using a JEOL JEM1010 TEM (JEOL Ltd, Tokyo, Japan) at 80 kV.

### **Molecular modelling of peptide 3D structures**

Structural modeling of buwchitin was completed using the PHYRE2 web portal (Kelley et al. 2015). Results were visualized using the PyMOL v1.7.6 program (Schrödinger 2010). The biophysical properties of buwchitin were predicted on the antimicrobial peptide database (APD2) (Wang et al. 2009).

### **Statistical analysis**

Two-way analysis of variance (ANOVA) with factors 'antimicrobial treatments' and 'time' was performed to determine whether there were significant changes in cell viability and membrane depolarization before and after treatment (Harmon 2011). This was followed by post-hoc multiple comparisons using Tukey's HSD (Honestly Significant Difference) test (Bender and Lange 2001, Feise 2002, Harmon 2011). Alpha ( $\alpha$ ) levels were set at  $P < 0.05$ .

## **Results**

### **Sequencing, cloning, expression and purification using in vivo expression systems**

The buwchitin gene was successfully PCR amplified using DNA from the fosmid clone, SAB PL27 L10/66. Bands of the correct size (expected size of 216 bp) were excised from the gel before proceeding to cloning. Electrophoresis results confirmed that the transformants carried the gene of the correct size, which was also confirmed by Sanger sequencing. The antimicrobial protein was expressed with an N-terminal 6xHis-Tag in *E. coli* to facilitate purification and investigation of its biochemical properties. Preliminary protein expression assay indicated that protein expression was optimal 4 h after induction (data not shown). SDS PAGE analysis of negative expression control (*E. coli* Top10 cells without plasmid) showed no protein expression bands while positive expression control (*E. coli* Top10 cells with pTrcHis-TOPO/lacZ) showed

expression of the protein with a correct size of 40 kDa (data not shown). Cultivation of buwchitin transformants were scaled up to a total volume of 1 L to produce cell pellets for protein purification. Recombinant proteins were purified in their native conditions to preserve their activity (Karakus et al. 2016). Figure 1 shows the SDS-PAGE analysis of the purification fractions for buwchitin. The purification protocol reproducibly yielded a total of ~0.8 mg of purified protein per liter of culture.

#### ***Antimicrobial and cytotoxic activity of buwchitin***

Buwchitin was active against *E. faecalis* with an MIC of 100-200 µg/ml (Table 2). It also showed some inhibition of *E. coli* growth (observed in growth curves), but no detectable MIC at the highest concentration tested. This may account for the low level of expression of buwchitin in the *E. coli* expression host. The highest concentration of buwchitin tested was 400 µg/ml due to low levels of protein expression and/or yield of purified protein. The killing activity of buwchitin against *E. faecalis* was calculated as a percentage ( $OD_{600nm}$ ) of surviving cells compared to the growth control. Only about  $30 \pm 1.4\%$  surviving *E. faecalis* cells remained after a 24 h incubation period ( $P < 0.05$ ). It would seem that buwchitin had a bacteriostatic effect against *E. faecalis* cells (Figure 2) as no change in *E. faecalis* cell density was observed over an incubation period of 24 h. Very little hemolytic effect ( $12.81 \pm 0.02\%$ ) was observed when sheep red blood cells were treated with buwchitin at a concentration twice as high as the MIC determined for *E. faecalis* (Table 3).

Buwchitin did not induce membrane depolarization in *E. faecalis* in the first 2 h of treatment. To determine whether the loss of viability in *E. faecalis* following exposure to buwchitin was accompanied by or was a result of changes in cell morphology and cell wall ultrastructure, TEM was performed. Electron micrographs of untreated *E. faecalis* at 1 h and 24 h reveal intact healthy cells. Electron micrographs of buwchitin treated *E. faecalis* cells at 1 h showed intact outer membranes with blebbing but no major damaging effects and cell morphology changes. In contrast, micrographs of buwchitin treated *E. faecalis* cells at 24 h revealed several changes in cell morphology including cell lysis and detachment of the cell interior from the cell envelope (Figure 3).

#### ***Structural modelling of buwchitin***

Modelling and visualization of the 3D conformation of buwchitin using PHYRE2 (Kelley et al. 2015) and PyMOL v1.7.6 (Schrödinger 2010) respectively, suggested that buwchitin is composed of a compact, all-helical, structure with major amphipathic helix connecting two smaller helices (Figure 4). The amphipathic helix agrees with a common structural feature of AMPs as the dual hydrophilic/hydrophobic nature allows the interaction and embedding of cellular membranes (Hancock and Sahl 2006). As predicted by the APD2 database, buwchitin (71AA) is positively charged (+9), has a total hydrophobicity ratio of 29% and total Arginine and Lysine ratio of 19%.

#### **Discussion**

Many currently used antibiotics were discovered by screening soil microorganisms that can be grown in the laboratory using standard microbial techniques for their antimicrobial activity (Ling et al. 2015). However, as natural product resources are practically inexhaustible, and approximately 99% of all species in external environments require more complex growth conditions than those provided using standard cultivation techniques, the majority of the world's microbial biodiversity remains to be explored (Harvey 2007, Berdy 2012, Lewis 2013). Several



recent studies already suggest that new organisms such as uncultured bacteria are likely to harbor new antimicrobials (Degen et al. 2014, Doroghazi et al. 2014, Gavrish et al. 2014, Wilson et al. 2014) and underexplored complex microbial communities, including the rumen, very likely represent rich sources of novel antimicrobials. These microbiomes have the potential to revive the platform of natural product discovery in a new culture-independent perspective, unbiased by the culturing aptitude of microbial species (Lewis 2012, McCann et al. 2014, Kang et al. 2015). The potential for application of metagenomics to biotechnology seems endless as functional screens can be used to identify new enzymes, antibiotics and other biological agents in libraries from diverse environments (Gillespie et al. 2002, Lorenz and Schleper 2002, Piel 2002, Voget et al. 2003, Berdy 2012).

In this study, we used a combination of functional and sequence based metagenomic screening strategies to prospect the rumen microbiome for novel antimicrobials as both strategies present advantages and limitations (Uchiyama and Miyazaki 2009). Whereas, sequence homology based analysis allows for the identification of new enzymes from a range of environments, it requires a certain sequence similarity to members from known gene families, therefore limiting novelty. Functional screening of metagenomic libraries on the other hand, does not depend on previous sequence knowledge and therefore has the potential to discover novel classes of genes coding for desired functions without depending on their sequence similarity to already known genes (Ferrer et al. 2009, Simon and Daniel 2009). We identified a novel antimicrobial gene, buwchitin, from the rumen microbiome and sought to express and characterize its antimicrobial activity against *E. faecalis*. Firstly, a fosmid-based cow rumen metagenomic clone library created from the solid attached bacteria of rumen content was functionally screened for antimicrobial activity. Clones with antimicrobial activity were subsequently sequenced to identify genes potentially involved in the antimicrobial activity observed in functional screens. Buwchitin, which was identified as a potential antimicrobial gene, was then expressed and further tested for antimicrobial activity. Buwchitin is a cationic (charge of +9),  $\alpha$ -helical peptide (as predicted by 3D modelling), 71 amino acids in length and has a molecular weight of 8.35 kDa. Expression of buwchitin yielded on average 0.8 mg of purified protein per liter of culture. This relatively low yield may be due to the inhibitory effects of buwchitin on *E. coli* growth. However, this yield falls in the range reported in literature where concentrations of 0.5-2.5 mg/ml (Guerreiro et al. 2008), and 0.8 mg/ml (Zorko et al. 2009, Pei et al. 2014) were retrieved from 1 L cultures by different approaches using Ni-NTA columns. It may be useful to explore alternative expression systems, such as *Pichia* sp. or *Aspergillus* sp. to improve the yield of the protein.

Buwchitin was active against *E. faecalis* JH2-2 with an MIC of 100-200  $\mu$ g/ml. This MIC is high when compared to antimicrobial proteins isolated and expressed using similar methods in other studies (Zorko et al. 2009, Elhag et al. 2017). Buwchitin (at MIC concentration) inhibited growth of *E. faecalis* cells with no change in *E. faecalis* cell density over a 24 h incubation period and has a minimum bactericidal concentration (MBC) of 200-400  $\mu$ g/ml, suggestive of a bacteriostatic killing activity. Although most antimicrobial peptides are bactericidal (Hancock 2001, Reddy et al. 2004, Lohner 2017), many examples of bacteriostatic antimicrobial peptides exist in literature (Mine et al. 2004, Choi et al. 2016). For example, the human  $\beta$ -defensin 2 (hBD-2) is bacteriostatic against *S. aureus* only at concentrations as high as 100  $\mu$ g/ml (Harder et al. 1997, Jung et al. 2011). Another example of a bacteriostatic antimicrobial peptide is the human lactoferricin (LfcinH) (Gifford et al. 2005). Furthermore, most antibacterials are potentially both bactericidal and bacteriostatic depending on bacterial

pathogen (Pankey and Sabath 2004). Further investigations into the mechanism underlying the bacteriostatic action of buwchitin would be necessary to come to a final conclusion about its accurate classification. Buwchitin had minimal hemolytic activity against sheep erythrocytes, suggesting that buwchitin may have selective activity against microbial cells. Despite these encouraging results, it will be necessary to carry out cytotoxicity assays on human and other mammalian cell lines to determine whether buwchitin can induce apoptosis and necrosis in cells (Paredes-Gamero et al. 2012). Very little or no membrane depolarization was observed in *E. faecalis* cells treated with buwchitin and TEM images of buwchitin treated cells showed intact outer membrane and very little changes in cell morphology after 1 h of treatment. Only after 24 h of treatment were large vacuoles in the cytoplasm and separation of the cell envelope observed. Given the low depolarizing activity of buwchitin, it would seem that membrane-destabilizing activity alone does not explain the antimicrobial activity of buwchitin. It is known that poly-cationic AMPs bound to teichoic acids including lipoteichoic (LTA) and wall teichoic acids (WTA) build a poly-anionic ladder and may initiate bacterial killing by facilitating the entry of peptides into the cytoplasmic membrane without membrane depolarization (Schneewind and Missiakas 2014, Malanovic and Lohner 2016). Further investigation into buwchitin teichoic acid binding and other mode of action studies are required to gain insights into its mechanism of action and the events leading to cell death.

Buwchitin is positively charged and has an amphiphilic structure with 29% hydrophobic residues as has been observed for many antimicrobial peptides (Hancock and Sahl 2006). This positive charge greatly facilitates the accumulation of AMPs at the polyanionic microbial cell surfaces and may be sufficient for antimicrobial action (Hancock and Sahl 2006), thus perturbing the membrane integrity. Some cationic peptides have been shown to translocate or form multimeric transmembrane channels promoting the membrane depolarization, which seems to contribute to their activity (Shai 1999, Bhattacharjya and Ramamoorthy 2009) at higher concentrations. The amphipathic nature of the predicted peptide structure and the observations in the TEM images is in agreement with this type of interaction, indicating that although buwchitin is not membrane destructive, it may interact with components of the cell envelope such as the enterococcal polysaccharide antigen. The formation of vacuoles in the cytoplasm also appear to support this idea. Still, at the current stage, it remains difficult to say which of the known membrane interaction and disruption models (i.e. barrel stave, carpet models, or micellar aggregate model) explains the activity of this peptide without further experimental evidence.

Further studies remain to be performed to enhance the antimicrobial phenotype of buwchitin. One potential strategy to improve the antimicrobial activity of buwchitin is the pepscan technology, in which shorter active fragments and optimized amino acid substitutions and/or modifications are identified by a scanning approach. These active peptide fragments identified by pepscan can then be SPOT-synthesized on cellulose membranes and systematically screened for antimicrobial activity (Hilpert et al. 2007, Winkler et al. 2009). The use of pepscan mapping and SPOT arrays has been shown to be useful for simultaneous optimization of peptides to generate new sequences that possess a variety of therapeutic and biological properties (Chico et al. 2010, Haney et al. 2015, Merino-Gracia et al. 2016, Ortega-Villaizan et al. 2016). Peptide improvements that might result from the pepscan technology might provide buwchitin derivatives with greater antimicrobial activity, similar to what has been achieved for other peptides in the literature (Knappe et al. 2016, Mikut et al. 2016). An evaluation of MICs against a panel of different bacterial species and *in vitro* stability studies in the presence of plasma or serum would also be beneficial. To explore the possible therapeutic relevance of buwchitin,

further *in vitro* cytotoxicity studies and *in vivo* studies with acute toxicity in mice at concentrations above the MIC would be required.

In conclusion, the data we generated and present here suggest that we discovered a novel rumen protein, buwchitin, with potential antimicrobial properties. It is furthermore possible that with substantial modification, this AMP might qualify as a potential antimicrobial agent for the treatment of *E. faecalis* infections, which would favor further investigation of the protein. This study also highlights the enormous value of prospecting the rumen microbiome, and other microbial communities for novel compounds to expand our limited antimicrobial drug toolbox.

#### **Conflict of interest**

There are no conflicts of interest to declare.

#### **Author contributions**

LO and SH conceived the project. LO and JC completed the laboratory work under supervision of SH, JE and CC. SG and LO completed the sequencing and downstream analysis of the sequences respectively. AC and NF helped LO with transmission electron microscopy and 3D structural modelling respectively. FP, OG and PG created the rumen fosmid metagenome library. MH, KH, CC and HM have provided valuable ideas into the project from conception. LO wrote the paper with input from all co-authors.

#### **Funding**

This project was funded partly by the Cross River State Government of Nigeria, the Life Sciences Research Network Wales, RCUK Newton Institutional Link Fund (172629373), and the BBSRC UK (BB/L026716/1).

#### **Acknowledgement**

We are grateful to Teri Davies for her technical assistance in setting up some experiments.

#### **References**

Arias, C. A. and B. E. Murray (2012). "The rise of the Enterococcus: beyond vancomycin resistance." *Nature reviews. Microbiology* **10**(4): 266-278.

Azevedo, A. C., C. B. P. Bento, J. C. Ruiz, M. V. Queiroz and H. C. Mantovani (2015). "Distribution and Genetic Diversity of Bacteriocin Gene Clusters in Rumen Microbial Genomes." *Applied and Environmental Microbiology* **81**(20): 7290-7304.

Baddour, L. M., W. R. Wilson, A. S. Bayer, V. G. Fowler, A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, D. C. Tong, J. M. Steckelberg, R. S. Baltimore, S. T. Shulman, J. C. Burns, D. A. Falace, J. W. Newburger, T. J. Pallasch, M. Takahashi and K. A. Taubert (2005). "Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and

Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America." *Circulation* **111**(23): e394-e434.

Bender, R. and S. Lange (2001). "Adjusting for multiple testing—when and how?" *Journal of clinical epidemiology* **54**(4): 343-349.

Berdy, J. (2012). "Thoughts and facts about antibiotics: Where we are now and where we are heading." *J Antibiot* **65**(8): 385-395.

Bhattacharjya, S. and A. Ramamoorthy (2009). "Multifunctional host defense peptides: functional and mechanistic insights from NMR structures of potent antimicrobial peptides." *FEBS J* **276**(22): 6465-6473.

Cahill, T. J. and B. D. Prendergast (2016.). "Infective endocarditis." *The Lancet* **387**(10021): 882-893.

Ch. Schroder, U., C. Beleites, C. Assmann, U. Glaser, U. Hubner, W. Pfister, W. Fritzsche, J. Popp and U. Neugebauer (2015). "Detection of vancomycin resistances in enterococci within 3 [half] hours." *Sci. Rep.* **5**(8217): DOI:10.1038/srep0821.

Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, S. K. Fridkin and T. Vancomycin-Resistant Staphylococcus aureus Investigative (2003). "Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene." *N Engl J Med* **348**(14): 1342-1347.

Chavers, L. S., S. A. Moser, W. H. Benjamin Jr, S. E. Banks, J. R. Steinhauer, A. M. Smith, C. N. Johnson, E. Funkhouser, L. P. Chavers, A. M. Stamm and K. B. Waites (2003). "Vancomycin-resistant enterococci: 15 years and counting." *Journal of Hospital Infection* **53**(3): 159-171.

Cherkasov, A., K. Hilpert, H. Jenssen, C. D. Fjell, M. Waldbrook, S. C. Mullaly, R. Volkmer and R. E. W. Hancock (2008). "Use of Artificial Intelligence in the Design of Small Peptide Antibiotics Effective against a Broad Spectrum of Highly Antibiotic-Resistant Superbugs." *ACS Chemical Biology* **4**(1): 65-74.

Chico, V., A. Martinez-Lopez, M. Ortega-Villaizan, A. Falco, L. Perez, J. M. Coll and A. Estepa (2010). "Pepscan mapping of viral hemorrhagic septicemia virus glycoprotein G major lineal determinants implicated in triggering host cell antiviral responses mediated by type I interferon." *Journal of Virology* **84**(14): 7140-7150.

Choi, H., N. Rangarajan and J. C. Weisshaar (2016). "Lights, Camera, Action! Antimicrobial Peptide Mechanisms Imaged in Space and Time." *Trends in microbiology* **24**(2): 111-122.

Church, D. C. (1993). *Ruminant animal: digestive physiology and nutrition.*, Prentice-Hall, Englewood Cliffs, NJ.

CLSI., C. a. L. S. I. (2012). *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically Ninth Edition: Approved Standard. M07-A9.* Wayne, PA, USA.

508 Czaplewski, L., R. Bax, M. Clokie, M. Dawson, H. Fairhead, V. A. Fischetti, S. Foster, B. F.  
509 Gilmore, R. E. Hancock, D. Harper, I. R. Henderson, K. Hilpert, B. V. Jones, A. Kadioglu, D.  
510 Knowles, S. Olafsdottir, D. Payne, S. Projan, S. Shaunak, J. Silverman, C. M. Thomas, T. J.  
511 Trust, P. Warn and J. H. Rex (2016). "Alternatives to antibiotics-a pipeline portfolio review."  
512 *Lancet Infect Dis* **16**(2): 239-251.

513 Dalgaard, P. and K. Koutsoumanis (2001). "Comparison of maximum specific growth rates  
514 and lag times estimated from absorbance and viable count data by different mathematical  
515 models." *J Microbiol Methods* **43**(3): 183-196.

516 Degen, D., Y. Feng, Y. Zhang, K. Y. Ebright, Y. W. Ebright, M. Gigliotti, H. Vahedian-  
517 Movahed, S. Mandal, M. Talaue, N. Connell, E. Arnold, W. Fenical and R. H. Ebright (2014).  
518 "Transcription inhibition by the depsipeptide antibiotic salinamide A." *Elife* **3**: e02451.

519 Doroghazi, J. R., J. C. Albright, A. W. Goering, K. S. Ju, R. R. Haines, K. A. Tchalukov, D. P.  
520 Labeda, N. L. Kelleher and W. W. Metcalf (2014). "A roadmap for natural product discovery  
521 based on large-scale genomics and metabolomics." *Nat Chem Biol* **10**(11): 963-968.

522 Ekkers, D. M., M. S. Cretoiu, A. M. Kielak and J. D. Elsas (2012). "The great screen anomaly-  
523 -a new frontier in product discovery through functional metagenomics." *Applied microbiology*  
524 *and biotechnology* **93**(3): 1005-1020.

525 Elhag, O., D. Zhou, Q. Song, A. A. Soomro, M. Cai, L. Zheng, Z. Yu and J. Zhang (2017).  
526 "Screening, Expression, Purification and Functional Characterization of Novel Antimicrobial  
527 Peptide Genes from *Hermetia illucens* (L.)." *PLOS ONE* **12**(1): e0169582.

528 Eliopoulos, G. M. and H. S. Gold (2001). "Vancomycin-Resistant Enterococci: Mechanisms  
529 and Clinical Observations." *Clinical Infectious Diseases* **33**(2): 210-219.

530 Feise, R. J. (2002). "Do multiple outcome measures require p-value adjustment?" *BMC*  
531 *Medical Research Methodology* **2**: 8-8.

532 Ferrer, M., A. Beloqui, K. N. Timmis and P. N. Golyshin (2009). "Metagenomics for mining  
533 new genetic resources of microbial communities." *Journal of molecular microbiology and*  
534 *biotechnology* **16**(1-2): 109-123.

535 Gasteiger, E., C. Hoogland, A. Gattiker, S. Duvaud, M. R. Wilkins, R. D. Appel and A.  
536 Bairoch, Eds. (2005). Protein Identification and Analysis Tools on the ExPASy Server; (In)  
537 John M. Walker (ed): The Proteomics Protocols Handbook,, Humana Press: 571-607.

538 Gavrish, E., C. S. Sit, S. Cao, O. Kandror, A. Spoering, A. Peoples, L. Ling, A. Fetterman, D.  
539 Hughes, A. Bissell, H. Torrey, T. Akopian, A. Mueller, S. Epstein, A. Goldberg, J. Clardy and  
540 K. Lewis (2014). "Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium  
541 tuberculosis by targeting the ATP-dependent protease ClpC1P1P2." *Chem Biol* **21**(4): 509-518.

542 Gifford, J. L., H. N. Hunter and H. J. Vogel (2005). "Lactoferricin." *Cellular and Molecular*  
543 *Life Sciences* **62**(22): 2588.

544 Gillespie, D. E., S. F. Brady, A. D. Bettermann, N. P. Cianciotto, M. R. Liles, M. R. Rondon,  
545 J. Clardy, R. M. Goodman and J. Handelsman (2002). "Isolation of antibiotics turbomycin a  
546 and B from a metagenomic library of soil microbial DNA." *Applied and Environmental*  
547 *Microbiology* **68**(9): 4301-4306.

548 Gilmore, M. S., F. Lebreton and W. van Schaik (2013). "Genomic transition of enterococci  
549 from gut commensals to leading causes of multidrug-resistant hospital infection in the  
550 antibiotic era." *Current Opinion in Microbiology* **16**(1): 10-16.

551 Guerreiro, C. I., C. M. Fontes, M. Gama and L. Domingues (2008). "Escherichia coli  
552 expression and purification of four antimicrobial peptides fused to a family 3 carbohydrate-  
553 binding module (CBM) from Clostridium thermocellum." *Protein Expr Purif* **59**(1): 161-168.

554 Hall, T. A. (1999). "BioEdit: a user-friendly biological sequence alignment editor and analysis  
555 program for Windows 95/98/NT." *Nucleic Acids Symposium Series* **41**: 95-98.

556 Hancock, R. E. and H. G. Sahl (2006). "Antimicrobial and host-defense peptides as new anti-  
557 infective therapeutic strategies." *Nat Biotechnol* **24**(12): 1551-1557.

558 Hancock, R. E. W. (2001). "Cationic peptides: effectors in innate immunity and novel  
559 antimicrobials." *The Lancet Infectious Diseases* **1**(3): 156-164.

560 Handelsman, J., M. R. Rondon, S. F. Brady, J. Clardy and R. M. Goodman (1998). "Molecular  
561 biological access to the chemistry of unknown soil microbes: a new frontier for natural  
562 products." *Chemistry & biology* **5**(10): R245-249.

563 Haney, E. F., S. C. Mansour, A. L. Hilchie, C. de la Fuente-Núñez and R. E. W. Hancock  
564 (2015). "High throughput screening methods for assessing antibiofilm and immunomodulatory  
565 activities of synthetic peptides." *Peptides* **71**: 276-285.

566 Harder, J., J. Bartels, E. Christophers and J. M. Schroder (1997). "A peptide antibiotic from  
567 human skin." *Nature* **387**(6636): 861-861.

568 Harmon, M. (2011). *Practical and Clear Graduate Statistics in Excel, The Complete Guide*.  
569 Florida, USA., Excel Master Series: 1066.

570 Harvey, A. L. (2007). "Natural products as a screening resource." *Current Opinion in Chemical*  
571 *Biology* **11**(5): 480-484.

572 Hazan, R., Y. A. Que, D. Maura and L. G. Rahme (2012). "A method for high throughput  
573 determination of viable bacteria cell counts in 96-well plates." *BMC Microbiol* **12**: 259.

574 Hess, M., A. Sczyrba, R. Egan, T. W. Kim, H. Chokhawala, G. Schroth, S. Luo, D. S. Clark,  
575 F. Chen, T. Zhang, R. I. Mackie, L. A. Pennacchio, S. G. Tringe, A. Visel, T. Woyke, Z. Wang  
576 and E. M. Rubin (2011). "Metagenomic discovery of biomass-degrading genes and genomes  
577 from cow rumen." *Science* **331**(6016): 463-467.

578 Hidron, A. I., J. R. Edwards, J. Patel, T. C. Horan, D. M. Sievert, D. A. Pollock, S. K. Fridkin,  
579 T. National Healthcare Safety Network and F. Participating National Healthcare Safety  
580 Network (2008). "NHSN annual update: antimicrobial-resistant pathogens associated with  
581 healthcare-associated infections: annual summary of data reported to the National Healthcare  
582 Safety Network at the Centers for Disease Control and Prevention, 2006-2007." *Infect Control*  
583 *Hosp Epidemiol* **29**(11): 996-1011.

584 Hilpert, K., D. F. H. Winkler and R. E. W. Hancock (2007). "Peptide arrays on cellulose  
585 support: SPOT synthesis, a time and cost efficient method for synthesis of large numbers of  
586 peptides in a parallel and addressable fashion." *Nat. Protocols* **2**(6): 1333-1349.

587 Hollenbeck, B. L. and L. B. Rice (2012). "Intrinsic and acquired resistance mechanisms in  
588 enterococcus." *Virulence* **3**(5): 421-569.

589 Huws, S. A., O. L. Mayorga, M. K. Theodorou, L. A. Onime, E. J. Kim, A. H. Cookson, C. J.  
590 Newbold and A. H. Kingston-Smith (2013). "Successional colonization of perennial ryegrass  
591 by rumen bacteria." *Letters in applied microbiology* **56**(3): 186-196.

592 Jenssen, H., P. Hamill and R. E. Hancock (2006). "Peptide antimicrobial agents." *Clin*  
593 *Microbiol Rev* **19**(3): 491-511.

594 Jung, S., J. Mysliwy, B. Spudy, I. Lorenzen, K. Reiss, C. Gelhaus, R. Podschun, M. Leippe  
595 and J. Grötzinger (2011). "Human  $\beta$ -Defensin 2 and  $\beta$ -Defensin 3 Chimeric Peptides Reveal  
596 the Structural Basis of the Pathogen Specificity of Their Parent Molecules." *Antimicrobial*  
597 *Agents and Chemotherapy* **55**(3): 954-960.

598 Kang, Y. M., M. K. Kim, J. M. An, M. A. Haque and K. M. Cho (2015). "Metagenomics of  
599 un-culturable bacteria in cow rumen: Construction of cel9E-xyn10A fusion gene by site-  
600 directed mutagenesis." *Journal of Molecular Catalysis B: Enzymatic* **113**(0): 29-38.

601 Karakus, C., M. Uslu, D. Yazici and B. A. Salih (2016). "Evaluation of immobilized metal  
602 affinity chromatography kits for the purification of histidine-tagged recombinant CagA  
603 protein." *Journal of Chromatography B* **1021**: 182-187.

604 Kau, A. L., S. M. Martin, W. Lyon, E. Hayes, M. G. Caparon and S. J. Hultgren (2005).  
605 "Enterococcus faecalis Tropism for the Kidneys in the Urinary Tract of C57BL/6J Mice."  
606 *Infection and Immunity* **73**(4): 2461-2468.

607 Kelley, L. A., S. Mezulis, C. M. Yates, M. N. Wass and M. J. E. Sternberg (2015). "The Phyre2  
608 web portal for protein modeling, prediction and analysis." *Nat. Protocols* **10**(6): 845-858.

609 Knappe, D., S. Ruden, S. Langanke, T. Tikkoo, J. Ritzer, R. Mikut, L. L. Martin, R. Hoffmann  
610 and K. Hilpert (2016). "Optimization of oncocin for antibacterial activity using a SPOT  
611 synthesis approach: extending the pathogen spectrum to Staphylococcus aureus." *Amino Acids*  
612 **48**(1): 269-280.

613 Leavis, H. L., M. J. Bonten and R. J. Willems (2006). "Identification of high-risk enterococcal  
614 clonal complexes: global dispersion and antibiotic resistance." *Curr Opin Microbiol* **9**(5): 454-  
615 460.

616 Lee, D. L., J. P. Powers, K. Pflegerl, M. L. Vasil, R. E. Hancock and R. S. Hodges (2004).  
617 "Effects of single D-amino acid substitutions on disruption of beta-sheet structure and  
618 hydrophobicity in cyclic 14-residue antimicrobial peptide analogs related to gramicidin S." *J*  
619 *Pept Res* **63**(2): 69-84.

620 Lehtinen, J., S. Jarvinen, M. Virta and E. M. Lilius (2006). "Real-time monitoring of  
621 antimicrobial activity with the multiparameter microplate assay." *J Microbiol Methods* **66**(3):  
622 381-389.

623 Lewis, K. (2012). "Antibiotics: Recover the lost art of drug discovery." *Nature* **485**(7399): 439-  
624 440.

625 Lewis, K. (2013). "Platforms for antibiotic discovery." *Nat Rev Drug Discov* **12**(5): 371-387.

626 Ling, L. L., T. Schneider, A. J. Peoples, A. L. Spoering, I. Engels, B. P. Conlon, A. Mueller,  
627 T. F. Schaberle, D. E. Hughes, S. Epstein, M. Jones, L. Lazarides, V. A. Steadman, D. R.  
628 Cohen, C. R. Felix, K. A. Fetterman, W. P. Millett, A. G. Nitti, A. M. Zullo, C. Chen and K.  
629 Lewis (2015). "A new antibiotic kills pathogens without detectable resistance." *Nature*  
630 **517**(7535): 455-459.

631 Lohner, K. (2017). "Membrane-active antimicrobial peptides as template structures for novel  
632 antibiotic agents." *Current Topics in Medicinal Chemistry* **17**(5): 508-519.

633 Lorenz, P. and C. Schleper (2002). "Metagenome—a challenging source of enzyme discovery."  
634 *Journal of Molecular Catalysis B: Enzymatic* **19–20**(0): 13-19.

635 Madrid, R. E. and C. J. Felice (2005). "Microbial biomass estimation." *Crit Rev Biotechnol*  
636 **25**(3): 97-112.

637 Malanovic, N. and K. Lohner (2016). "Antimicrobial Peptides Targeting Gram-Positive  
638 Bacteria." *Pharmaceuticals* **9**(3): 59.

639 McCann, J. C., T. A. Wickersham and J. J. Loor (2014). "High-throughput Methods Redefine  
640 the Rumen Microbiome and Its Relationship with Nutrition and Metabolism." *Bioinform Biol*  
641 *Insights* **8**: 109-125.

642 Merino-Gracia, J., H. Zamora-Carreras, M. Bruix and I. Rodríguez-Crespo (2016). "Molecular  
643 Basis for the Protein Recognition Specificity of the Dynein Light Chain DYNLT1/Tctex1:  
644 Characterization of the interaction with activin receptor IIB." *Journal of Biological Chemistry*  
645 **291**(40): 20962-20975.

646 Mikut, R., S. Ruden, M. Reischl, F. Breitling, R. Volkmer and K. Hilpert (2016). "Improving  
647 short antimicrobial peptides despite elusive rules for activity." *Biochimica et Biophysica Acta*  
648 *(BBA) - Biomembranes* **1858**(5): 1024-1033.

649 Mine, Y., F. Ma and S. Lauriau (2004). "Antimicrobial Peptides Released by Enzymatic  
650 Hydrolysis of Hen Egg White Lysozyme." *Journal of Agricultural and Food Chemistry* **52**(5):  
651 1088-1094.

652 O'Neill, J. (2016). Tackling Drug-Resistant Infections Globally: final report and  
653 recommendations. *The review on antimicrobial resistance*. J. O'Neill. U.K.

654 Ortega-Villaizan, M., V. Chico, A. Martinez-Lopez, P. Garcia-Valtanen, J. M. Coll and A.  
655 Estepa (2016). "Development of new therapeutical/adjuvant molecules by pepscan mapping of  
656 autophagy and IFN inducing determinants of rhabdoviral G proteins." *Molecular Immunology*  
657 **70**: 118-124.

658 Oyama, L. B. (2015). *Prospecting Rumen Bacteria for Novel Antimicrobials*. Doctor of  
659 Philosophy in Biological Sciences PhD, Aberystwyth University: 302.

660 Pankey, G. A. and L. D. Sabath (2004). "Clinical Relevance of Bacteriostatic versus  
661 Bactericidal Mechanisms of Action in the Treatment of Gram-Positive Bacterial Infections."  
662 *Clinical Infectious Diseases* **38**(6): 864-870.

663 Paredes-Gamero, E. J., M. N. C. Martins, F. A. M. Cappabianco, J. S. Ide and A. Miranda  
664 (2012). "Characterization of dual effects induced by antimicrobial peptides: Regulated cell



665 death or membrane disruption." *Biochimica et Biophysica Acta (BBA) - General Subjects*  
666 **1820**(7): 1062-1072.

667 Pei, Z., X. Sun, Y. Tang, K. Wang, Y. Gao and H. Ma (2014). "Cloning, expression, and  
668 purification of a new antimicrobial peptide gene from *Musca domestica* larva." *Gene* **549**(1):  
669 41-45.

670 Petersen, T. N., S. Brunak, G. von Heijne and H. Nielsen (2011). "SignalP 4.0: discriminating  
671 signal peptides from transmembrane regions." *Nat Meth* **8**(10): 785-786.

672 Piel, J. (2002). "A polyketide synthase-peptide synthetase gene cluster from an uncultured  
673 bacterial symbiont of *Paederus* beetles." *Proc Natl Acad Sci U S A* **99**(22): 14002-14007.

674 Prive, F., C. J. Newbold, N. N. Kaderbhai, S. G. Girdwood, O. V. Golyshina, P. N. Golyshin,  
675 N. D. Scollan and S. A. Huws (2015). "Isolation and characterization of novel lipases/esterases  
676 from a bovine rumen metagenome." *Appl Microbiol Biotechnol*.

677 Reddy, K. V. R., R. D. Yedery and C. Aranha (2004). "Antimicrobial peptides: premises and  
678 promises." *International Journal of Antimicrobial Agents* **24**(6): 536-547.

679 Ross, E. M., P. J. Moate, C. R. Bath, S. E. Davidson, T. I. Sawbridge, K. M. Guthridge, B. G.  
680 Cocks and B. J. Hayes (2012). "High throughput whole rumen metagenome profiling using  
681 untargeted massively parallel sequencing." *BMC Genet* **13**: 53.

682 Russell, J. B. and H. C. Mantovani (2002). "The bacteriocins of ruminal bacteria and their  
683 potential as an alternative to antibiotics." *Journal of molecular microbiology and biotechnology*  
684 **4**(4): 347-355.

685 Schloss, P. D. and J. Handelsman (2003). "Biotechnological prospects from metagenomics."  
686 *Current opinion in biotechnology* **14**(3): 303-310.

687 Schneewind, O. and D. Missiakas (2014). "Lipoteichoic Acids, Phosphate-Containing  
688 Polymers in the Envelope of Gram-Positive Bacteria." *Journal of Bacteriology* **196**(6): 1133-  
689 1142.

690 Schrödinger, L. L. C. (2010). The PyMOL Molecular Graphics System, Version 1.7.6.

691 Shai, Y. (1999). "Mechanism of the binding, insertion and destabilization of phospholipid  
692 bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic  
693 peptides." *Biochim Biophys Acta* **1462**(1-2): 55-70.

694 Simon, C. and R. Daniel (2009). "Achievements and new knowledge unraveled by  
695 metagenomic approaches." *Applied microbiology and biotechnology* **85**(2): 265-276.

696 Sirohi, S. K., N. Singh, S. S. Dagar and A. K. Puniya (2012). "Molecular tools for deciphering  
697 the microbial community structure and diversity in rumen ecosystem." *Appl Microbiol*  
698 *Biotechnol* **95**(5): 1135-1154.

699 Uchiyama, T. and K. Miyazaki (2009). "Functional metagenomics for enzyme discovery:  
700 challenges to efficient screening." *Curr Opin Biotechnol* **20**(6): 616-622.

701 van Harten, R. M., R. J. L. Willems, N. I. Martin and A. P. A. Hendrickx (2017). "Multidrug-  
702 Resistant Enterococcal Infections: New Compounds, Novel Antimicrobial Therapies?" *Trends*  
703 *in Microbiology* **25**(6): 467-479.

704 Voget, S., C. Leggewie, A. Uesbeck, C. Raasch, K. E. Jaeger and W. R. Streit (2003).  
705 "Prospecting for Novel Biocatalysts in a Soil Metagenome." *Applied and Environmental*  
706 *Microbiology* **69**(10): 6235-6242.

707 Wang, G., X. Li and Z. Wang (2009). "APD2: the updated antimicrobial peptide database and  
708 its application in peptide design." *Nucleic Acids Research* **37**(Database issue): D933-D937.

709 Wheeler, D. L., D. M. Church, S. Federhen, A. E. Lash, T. L. Madden, J. U. Pontius, G. D.  
710 Schuler, L. M. Schriml, E. Sequeira, T. A. Tatusova and L. Wagner (2003). "Database  
711 resources of the National Center for Biotechnology." *Nucleic Acids Res* **31**(1): 28-33.

712 WHO (2017). WHO publishes list of bacteria for which new antibiotics are urgently needed.  
713 Geneva Switzerland, World Health Organisation.

714 Wiegand, I., K. Hilpert and R. E. Hancock (2008). "Agar and broth dilution methods to  
715 determine the minimal inhibitory concentration (MIC) of antimicrobial substances." *Nat*  
716 *Protoc* **3**(2): 163-175.

717 Wiesner, J. and A. Vilcinskas (2010). "Antimicrobial peptides: the ancient arm of the human  
718 immune system." *Virulence* **1**(5): 440-464.

719 Wilson, M. C., T. Mori, C. Ruckert, A. R. Uria, M. J. Helf, K. Takada, C. Gernert, U. A.  
720 Steffens, N. Heycke, S. Schmitt, C. Rinke, E. J. Helfrich, A. O. Brachmann, C. Gurgui, T.  
721 Wakimoto, M. Kracht, M. Crusemann, U. Hentschel, I. Abe, S. Matsunaga, J. Kalinowski, H.  
722 Takeyama and J. Piel (2014). "An environmental bacterial taxon with a large and distinct  
723 metabolic repertoire." *Nature* **506**(7486): 58-62.

724 Winkler, D. F. H., K. Hilpert, O. Brandt and R. E. W. Hancock (2009). Synthesis of Peptide  
725 Arrays Using SPOT-Technology and the CelluSpots-Method. *Peptide Microarrays: Methods*  
726 *and Protocols*. M. Cretich and M. Chiari. Totowa, NJ, Humana Press: 157-174.

727 Wu, M. and R. E. Hancock (1999). "Interaction of the cyclic antimicrobial cationic peptide  
728 bactenecin with the outer and cytoplasmic membrane." *J Biol Chem* **274**(1): 29-35.

729 Wu, M., E. Maier, R. Benz and R. E. Hancock (1999). "Mechanism of interaction of different  
730 classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic  
731 membrane of Escherichia coli." *Biochemistry* **38**(22): 7235-7242.

732 Young, S., B. Nayak, S. Sun, B. D. Badgley, J. R. Rohr and V. J. Harwood (2016).  
733 "Vancomycin-Resistant Enterococci and Bacterial Community Structure following a Sewage  
734 Spill into an Aquatic Environment." *Applied and Environmental Microbiology* **82**(18): 5653-  
735 5660.

736 Zorko, M., B. Japelj, I. Hafner-Bratkovic and R. Jerala (2009). "Expression, purification and  
737 structural studies of a short antimicrobial peptide." *Biochim Biophys Acta* **1788**(2): 314-323.

738

**Table 1. ORFs with homology to antimicrobial (biosynthetic) protein coding genes in rumen metagenome fosmids.** All ORFs are from contig 1 of each fosmid and are in the 5'-3' direction.

Fosmid Plate ID/ORF	Gene name	Protein size (AA)	Most similar homolog (e-value)	Putative function	Identity (overlapped AA)/% similarity
SABPL5 C17/11	Gene 6	184	<i>Prevotella ruminicola</i> 23 WP_013063463.1 (3e-104) <i>Butyrivibrio crossotus</i> CAG:259 WP_021960962.1 (2e-33)	<b>4'-phosphopantetheinyl transferase family protein</b> Synthesis of unusual molecules including polyketides, atypical fatty acids, and antibiotics <b>putative biosurfactants production protein</b>	140/184(76%) 58/161(36%)
SABPL12(1) C3/9	Gene 17A	350	<i>Prevotella</i> sp. CDD20257.1(0.0)	<b>3-dehydroquinate synthase</b> DHQS represents a potential target for the development of novel and selective antimicrobial agents	250/346(72%)
SABPL12(1) C3/50	Gene 17B	80	<i>Pseudomonas putida</i> S16 NP_744149.1 (1.4)	<b>Colicin V</b> production protein	19/61(31%)
SABPL27 L10/66	Buwchitin	71	<i>Streptomyces mobaraensis</i> WP_004942604.1 e-value 5.0	<b>penicillin</b> amidase Penicillin biosynthesis and metabolism	16/43(37%)
SABPL27 L10/73	Gene 68	68	<i>Ornithinibacillus scapharcae</i> YP_004810705.1 e value 8.4	<b>beta-lactam antibiotic</b> acylase Penicillin biosynthesis and metabolism	22/63(35%)

**Table 2 Minimum inhibitory concentration (MIC) of buwchitin and comparator antimicrobial agents (n = 6)), > (precedes the highest concentration tested). Highest concentration of buwchitin tested is 400 µg/ml due to low protein yield.**

Peptide ID	MICs (µg/ml)			
	<i>Sal. typhimurium</i>	<i>E. coli</i>	<i>S. aureus</i>	<i>E. faecalis</i>
Polymyxin B sulfate	1.95	1.95	250	31.25
Ciprofloxacin	0.12	0.06	>250	62.5
Vancomycin hydrochloride	250	125	0.98	62.5
Buwchitin	>400	>400	>400	100-200

**Table 3. Hemolytic activity of buwchitin against sheep erythrocytes *E. faecalis* cells** resuspended and diluted (4%) in PBS were treated with buwchitin (1x MIC) or 0.1% (v/v) Triton X-100 and hemolysis was monitored at OD<sub>450nm</sub> at 1 h after incubation at 37°C, (values from three independent replicates and showing the standard deviation).

Concentration (µg/ml)	% hemolysis
400	12.81 ± 0.02
200	9.69 ± 0.09
100	5.23 ± 0.08
50	4.12 ± 0.06
25	4.15 ± 0.06
12.5	3.08 ± 0.03
6.25	2.80 ± 0.02
3.125	3.11 ± 0.06

## 690 **Figure Legends**


691 **Figure 1.** SDS-PAGE analysis of purification steps of buwchitin protein expressed in *E. coli*  
692 TOP10 cells on a 20% denaturing polyacrylamide gel (4 h after induction with 1 mM IPTG).  
693 Lane 1: protein molecular weight marker, Lane 2: cell lysate, Lane 3: supernatant, Lane 4:  
694 Wash step, Lane 5: eluted buwchitin protein. The arrow indicates band of purified protein of  
695 interest. Expected size is 8.35 ( $\pm 3$ -4 kDa from His-tag).

696 **Figure 2** Growth rate of *E. faecalis* in presence of antibacterial agents. Growth rate was  
697 determined by monitoring cell density at OD600<sub>nm</sub> in three independent measurements at 1x  
698 MIC concentration. Error bars represent the standard deviation.


699 **Figure 3.** Representative transmission electron micrographs of *E. faecalis*. **A)** Untreated *E.*  
700 *faecalis* cells at 1 h. **B)** Buwchitin treated cells (200  $\mu$ g/ml) at 1 h. **C)** Untreated *E. faecalis* at  
701 24 h. **D)** Buwchitin treated cells (200  $\mu$ g/ml) at 24 h. Scale bars on micrographs.

702 **Figure 4.** Structural model of buwchitin (grey) in cartoon and surface representation. Side  
703 chains of selected amino-acid colored according to atom type (N: blue; C: white; O: red). The  
704 N- terminus (Nt) and C- terminus (Ct) is also shown. Figure prepared using PyMol  
705 (Schrödinger 2010).

706  
707  
708  
709




**Figure 1.** SDS-PAGE analysis of purification steps of buwchitin protein expressed in *E. coli* TOP10 cells on a 20% denaturing polyacrylamide gel (4 h after induction with 1 mM IPTG). 10  $\mu$ l and 20  $\mu$ l molecular weight markers and proteins loaded in gel respectively. Lane 1: protein molecular weight marker, Lane 2: cell lysate, Lane 3: supernatant, Lane 4: Wash step, Lane 5: eluted buwchitin protein. The arrow indicates band of purified protein of interest. Expected size is 8.35 ( $\pm$ 3-4 kDa from His-tag).




**Figure 2.** Growth rate of *E. faecalis* in presence of antibacterial agents. Growth rate was determined by monitoring cell density at OD600<sub>nm</sub> in three independent measurements at 1x MIC concentration. Error bars represent the standard deviation.





**Figure 3.** Representative transmission electron micrographs of *E. faecalis*. **A)** Untreated *E. faecalis* cells at 1 h. **B)** Buwchitin treated cells (200 µg/ml) at 1 h. **C)** Untreated *E. faecalis* at 24 h. **D)** Buwchitin treated cells (200 µg/ml) at 24 h. Scale bars on micrographs.



**Figure 4.** Structural model of buwchitin (grey) in cartoon and surface representation. Side chains of selected amino-acid colored according to atom type (N: blue; C: white; O: red). The N- terminus (Nt) and C- terminus (Ct) is also shown. Figure prepared using PyMol (Schrödinger 2010).